Key result
The treatment effect of ticagrelor versus prasugrel on death, myocardial infarction, or stroke did not differ across platelet count quartiles.
Why the study?
The relative efficacy and safety of ticagrelor and prasugrel based dual antiplatelet therapy strategies according to platelet count in ACS patients have not been defined.
Does ticagrelor compared to prasugrel improve ischemic outcomes or alter bleeding risk differently based on baseline platelet count in patients with acute coronary syndromes?
RCT (n=3,943)
randomized
Does ticagrelor compared to prasugrel improve ischemic outcomes or alter bleeding risk differently based on baseline platelet count in patients with acute coronary syndromes?
Baseline platelet count does not significantly modify the relative efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Baseline platelet count does not appear to modify ticagrelor-prasugrel effects in ACS; leaves open whether other factors should guide P2Y12 inhibitor selection.
Background The relative efficacy and safety of ticagrelor and prasugrel based dual antiplatelet therapy strategies according to the platelet count (PC) in patients with acute coronary syndromes (ACS) have not been defined. Methods This is a posthoc analysis of the ISAR-REACT 5 trial, in which patients presenting with ACS were randomized to treatment with ticagrelor versus prasugrel. Patients were divided into quartiles according to PC. The primary endpoint was incidence of death, myocardial infarction, or stroke, and the safety endpoint was incidence of BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 12 months. Results A total of 3,943 patients with known PC (997 patients in quartile 1 (Q1), 1,003 in quartile 2 (Q2) [205 ± 10.3 × 109/L], 961 patients in quartile 3 (Q3) [241 ± 11.7 × 109/L], and 982 patients in quartile 4 (Q4) [317 ± 68.6 × 109/L]). There was no significant interaction between treatment arm (ticagrelor vs. prasugrel) and PC group with respect to primary endpoint (Q1: 8.8 vs. 6.3%, hazard ratio [HR] =1.41, 95% confidence interval [CI]: 0.89–2.23; p = 0.148; Q2: 9.9 vs. 5.8%, HR = 1.68, 95% CI: 1.06–2.66; p = 0.027; Q3: 7.8 vs. 5.5%, HR = 1.43, 95% CI: 0.87–2.37; p = 0.159; Q4: 10.1 vs. 10.1%, HR = 1.05, 95% CI: 0.71–1.57; p = 0.799; p for interaction [p int] = 0.482) and with respect to bleeding endpoint (Q1: 5.8 vs. 4.2%, HR = 1.41, 95% CI: 0.76–2.63; p = 0.279; Q2: 6.4 vs. 3.7%, HR = 1.62, 95% CI: 0.85–2.06; p = 0.140; Q3: 4.4 vs. 3.0%, HR = 1.53, 95% CI: 0.73–3.18; p = 0.258; Q4: 5.6 vs. 8.5%, HR = 0.67, 95% CI: 0.40–1.14; p = 0.138, p int = 0.102). Conclusions In this analysis, incidences of ischemic and bleeding events at 12 months are comparable across quartiles of platelet count.
No takes yet. Share an insight, caveat, or question.
Koch et al. (2022) conducted an RCT in Acute coronary syndromes (n=3,943). Ticagrelor vs. Prasugrel was evaluated on Incidence of death, myocardial infarction, or stroke (p=0.482). The treatment effect of ticagrelor versus prasugrel on death, myocardial infarction, or stroke did not differ across platelet count quartiles.
Synapse has enriched 10 related papers. Consider them for comparative context: